Ubs Group Ag Dyne Therapeutics, Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 357,754 shares of DYN stock, worth $4.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
357,754
Previous 540,112
33.76%
Holding current value
$4.28 Million
Previous $12.7 Million
70.59%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding DYN
# of Institutions
216Shares Held
116MCall Options Held
322KPut Options Held
66.2K-
Janus Henderson Group PLC London, X010.4MShares$124 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$116 Million2.11% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$109 Million27.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.41MShares$88.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$88.3 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $619M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...